How should young patients with rhabdomyosarcoma be managed in the absence of a clinical trial?  

-Are there settings where group II disease does not need RT?
-Are there additional genetic alterations in fusion negative RMS patients that can be used to further risk-adapt therapy?
-Should we uniformly apply RT guidelines regardless of age (what about infants)?
-Should RT doses change in light of the higher failure w/low dose cyclophosphamide or should we use higher doses of cyclo?



Answer from: Radiation Oncologist at Academic Institution